Aims: this study aimed to evaluate the role of commiphora mol mol and doxycycline in the prophylaxis of spontaneous bacterial peritonitis in cirrhotic patients. Methodology: sixty ascetic cirrhotic patients f r o m National Liver Institute, Menofiya University (Shebeen El-Kom-Egypt) with a history of at least one previous episode of SBP were included in blinded randomized clinical study. Patients were divided into four groups in a fashion; each group consists of 15 patients. Group one received ciprofloxacin (control group), group two received doxycycline, group three received commiphora mol mol and group four received a combination of commiphora mol mol and doxycycline for six months. Serum interleukin 6 (IL 6) and C Reactive Protein (CRP) level were the primary inflammatory markers of the study to evaluate the effect of the studied medications. Results: both IL-6 and CRP levels showed significant decrease three and six months after treatment in all studied groups (P<0.05). Group four showed a significant decrease in IL 6 and CRP level compared with other three groups (P<0.05). Conclusion: the results of the current study strongly support the efficacy of doxycycline and Commiphora molmol as a primary prophylactic therapy in patients with SBP. Furthermore, commiphora mol mol/doxycycline combination was the most effective and showed synergistic effect which may be useful in decrease emergence of resistant strains.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.